CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment - Jin, Yan; Desta, Zeruesenay; Stearns, Vered; Ward, Bryan; Ho, Herbert; Lee, Kyung-Hoon; Skaar, Todd; Storniolo, Anna Maria; Li, Lang; Araba, Adjei; Blanchard, Rebecca; Nguyen, Anne; et al. (JNCI : Journal of the National Cancer Institute, 2005)
Keywords: Adult; Aged; Antidepressants; Antidepressive Agents, Second-Generation - administration & dosage; Antidepressive Agents, Second-Generation - metabolism; Antineoplastic agents; Antineoplastic Agents, Hormonal - administration & dosage; Antineoplastic Agents, Hormonal - blood; Antineoplastic Agents, Hormonal - metabolism; Aryl Hydrocarbon Hydroxylases - genetics; Arylsulfotransferase - genetics; Biological and medical sciences; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - enzymology; Breast Neoplasms - metabolism; Chemotherapy; Chemotherapy, Adjuvant; Cyclohexanols - metabolism; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6 - genetics; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System - genetics; Drug Administration Schedule; Drug therapy; Enzyme Inhibitors - metabolism; Estrogen Receptor Modulators - administration & dosage; Estrogen Receptor Modulators - blood; Estrogen Receptor Modulators - metabolism; Female; Genotype; Humans; Medical sciences; Metabolism; Middle Aged; Pharmacology. Drug treatments; Prospective Studies; Serotonin Uptake Inhibitors - administration & dosage; Serotonin Uptake Inhibitors - metabolism; Side effects; Tamoxifen - administration & dosage; Tamoxifen - blood; Tamoxifen - metabolism; Time Factors; Tumors; Venlafaxine Hydrochloride; Antineoplastic agent; Human; Genetic variability; Enzyme; Isozyme; Serotonin antagonist; Cytochrome P450; Antiestrogen; Adjuvant treatment; Genotype; Breast cancer; Antihormone; Malignant tumor; Metabolism; Tamoxifene; Mammary gland diseases; Chemotherapy; Cancerology; Antidepressant agent; Pharmacokinetics; Non steroid compound; Polymorphism